{"id":"NCT01614899","sponsor":"Sumitomo Pharma Co., Ltd.","briefTitle":"A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","officialTitle":"Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07-02","primaryCompletion":"2014-11-17","completion":"2014-11-17","firstPosted":"2012-06-08","resultsPosted":"2018-10-19","lastUpdate":"2022-04-12"},"enrollment":457,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"SM-13496 40mg","otherNames":[]},{"type":"DRUG","name":"SM-13496 80mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SM-13496 40mg","type":"EXPERIMENTAL"},{"label":"SM-13496 80mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.","primaryOutcome":{"measure":"Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6","timeFrame":"Baseline and 6 week","effectByArm":[{"arm":"SM-13496 (Lurasidone HCl) 40mg","deltaMin":-17.9,"sd":1.72},{"arm":"SM-13496 (Lurasidone HCl) 80mg","deltaMin":-17.3,"sd":1.67},{"arm":"Placebo","deltaMin":-13.1,"sd":1.72}],"pValues":[{"comp":"OG000 vs OG002","p":"0.050"},{"comp":"OG001 vs OG002","p":"0.080"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":4,"countries":["Japan","Malaysia","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":150},"commonTop":["Akathisia","Headache","Nausea","Constipation","Anxiety"]}}